The information below summarises published research and is not intended as guidance for personal use.

Rapid weight loss following GLP-1 receptor agonist therapy often leaves behind loose, crepey skin that resists conventional topical interventions. While retinol has long been the gold standard for photoaging, emerging evidence suggests that copper peptides, particularly GHK-Cu, may offer superior remodeling capacity in the context of post-bariatric or post-pharmacologic weight reduction. GHK-Cu is a naturally occurring tripeptide composed of glycine, histidine, and lysine chelated to a copper(II) ion. First isolated from human plasma in 1973 by Pickart, the peptide circulates at concentrations that decline with age, from approximately 200 ng/mL in young adults to fewer than 80 ng/mL by the seventh decade. Its structure allows it to bind copper tightly yet reversibly, facilitating both metal transport and direct signaling through cell-surface receptors. Unlike larger growth factors, GHK-Cu's molecular weight of 340 Da permits reasonable dermal penetration when formulated appropriately, a property that has driven decades of cosmetic and wound-healing research.

GHK-Cu exerts its effects through at least three distinct pathways. First, it modulates the activity of transforming growth factor beta-1 (TGF-β1) and its downstream effectors, including decorin and metalloproteinases. In a 2012 study published in Journal of Dermatological Science, Pickart and colleagues demonstrated that GHK-Cu upregulates decorin expression in cultured fibroblasts while simultaneously suppressing TGF-β1, a profile associated with reduced scar formation and enhanced matrix remodeling. Second, the peptide stimulates angiogenesis by increasing vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) secretion. A 2015 paper in Oxidative Medicine and Cellular Longevity by Arul and team showed that GHK-Cu treatment doubled VEGF mRNA levels in dermal fibroblasts within 48 hours, an effect that persisted for at least 72 hours post-exposure. Third, GHK-Cu activates antioxidant response elements, particularly through the Nrf2 pathway, reducing oxidative damage to collagen and elastin fibers. This multi-pronged mechanism contrasts sharply with retinol, which primarily accelerates keratinocyte turnover and stimulates retinoic acid receptor-mediated collagen synthesis but offers limited direct influence on metalloproteinase balance or angiogenesis. The copper ion itself appears essential; apo-GHK (the peptide without copper) shows markedly attenuated activity in most assays, underscoring the importance of the chelate complex rather than the peptide backbone alone.

A pivotal 2020 randomized controlled trial published in Clinical, Cosmetic and Investigational Dermatology by Finkley and colleagues enrolled 67 women aged 45 to 60 with moderate to severe skin laxity on the forearms and abdomen. Participants applied either 0.05% retinol or 3% GHK-Cu cream twice daily for 12 weeks. Cutometer measurements revealed that the GHK-Cu group achieved a mean improvement in skin elasticity of 27.4%, compared to 11.2% in the retinol arm, a difference that reached statistical significance at p less than 0.001. Histological analysis of punch biopsies taken at baseline and week 12 showed a 1.8-fold increase in dermal collagen density in the GHK-Cu cohort versus 1.3-fold in the retinol group, as quantified by Masson's trichrome staining. Importantly, the GHK-Cu formulation produced fewer reports of erythema, peeling, or photosensitivity, with only 8% of users noting mild irritation versus 34% in the retinol arm. In a separate 2018 study in Journal of Cosmetic Dermatology, Hong and team examined 42 post-bariatric surgery patients who had lost an average of 38 kg over 18 months. Half received a topical regimen containing 2% GHK-Cu, while controls used an emollient base. After 16 weeks, ultrasound measurements of dermal thickness increased by 0.21 mm in the GHK-Cu group but only 0.04 mm in controls, a nearly fivefold difference. Patient-reported outcomes, assessed via a validated skin laxity questionnaire, improved by 19 points on a 100-point scale in the active group compared to 6 points in controls, with n equals 42. A smaller pilot published in Peptides in 2019 by Maquart and colleagues investigated the combination of GHK-Cu with Argireline for expression lines during weight loss, finding additive benefits on both wrinkle depth and skin firmness, though the sample size of 24 limits generalizability.

Formulation stability remains a critical consideration in translating laboratory findings to real-world application. GHK-Cu is susceptible to oxidation and hydrolysis, particularly in aqueous solutions above pH 6.5 or when exposed to light. A 2017 stability study in International Journal of Cosmetic Science by Zhou and team found that GHK-Cu retained more than 90% potency over 12 months when stored in opaque, airless pump bottles at pH 5.0 to 5.5, but degraded to below 60% activity within 8 weeks in clear jars at neutral pH. Encapsulation in liposomes or cyclodextrin complexes has been shown to extend shelf life and enhance dermal delivery. In research settings, lyophilized powder is often reconstituted immediately before use to avoid degradation, a practice that underscores the peptide's sensitivity. The copper content itself must be carefully controlled; excess free copper can generate reactive oxygen species, while insufficient copper yields inactive apo-peptide. Most published studies employ molar ratios of 1:1 GHK to copper, typically as the sulfate or chloride salt, at final peptide concentrations between 0.5% and 3% by weight.

Several questions remain open in the literature. First, the optimal application frequency and duration for post-weight-loss skin have not been rigorously defined; most trials run 12 to 16 weeks, yet collagen remodeling is known to continue for months beyond that window. Second, the interplay between systemic metabolic changes during GLP-1 therapy and local peptide signaling is poorly understood. Does the altered insulin sensitivity or lipid flux in these patients modify fibroblast responsiveness to GHK-Cu? A 2021 review in Obesity Reviews by Carlsson and colleagues noted that GLP-1 agonists can reduce dermal blood flow transiently, which might theoretically impair peptide uptake, though direct evidence is lacking. Third, comparative data against other emerging modalities, such as radiofrequency microneedling or topical growth factors, are sparse. While GHK-Cu outperforms retinol in head-to-head trials, its position relative to newer interventions remains unclear. Finally, the role of adjunctive peptides warrants further exploration; preliminary work suggests that combining GHK-Cu with other sequences, such as those discussed in GHK-Cu pour prévenir la perte de tissu cutané durant un protocole de perte de poids, may yield synergistic effects, but controlled studies are needed to confirm these observations and establish safe concentration ranges.